Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. more
Time Frame | ADPT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.43% | -2.06% | -0.55% |
1-Month Return | 27.56% | -1.92% | 2.72% |
3-Month Return | 29.5% | -10.4% | 7.66% |
6-Month Return | 93.83% | -4.6% | 10.15% |
1-Year Return | 26.75% | 4.06% | 27.53% |
3-Year Return | -78.51% | 1.94% | 32.31% |
5-Year Return | -80.71% | 36.48% | 89.2% |
10-Year Return | -85.19% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M | [{"date":"2019-12-31","value":45.91,"profit":true},{"date":"2020-12-31","value":53.09,"profit":true},{"date":"2021-12-31","value":83.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.89,"profit":true}] |
Cost of Revenue | 22.27M | 22.53M | 49.30M | 57.91M | 75.55M | [{"date":"2019-12-31","value":29.48,"profit":true},{"date":"2020-12-31","value":29.82,"profit":true},{"date":"2021-12-31","value":65.25,"profit":true},{"date":"2022-12-31","value":76.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 62.80M | 75.85M | 105.04M | 127.40M | 94.72M | [{"date":"2019-12-31","value":49.29,"profit":true},{"date":"2020-12-31","value":59.54,"profit":true},{"date":"2021-12-31","value":82.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.35,"profit":true}] |
Gross Margin | 73.82% | 77.10% | 68.06% | 68.75% | 55.63% | [{"date":"2019-12-31","value":95.74,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":88.27,"profit":true},{"date":"2022-12-31","value":89.17,"profit":true},{"date":"2023-12-31","value":72.15,"profit":true}] |
Operating Expenses | 141.19M | 228.67M | 314.01M | 327.58M | 321.76M | [{"date":"2019-12-31","value":43.1,"profit":true},{"date":"2020-12-31","value":69.8,"profit":true},{"date":"2021-12-31","value":95.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.22,"profit":true}] |
Operating Income | (78.39M) | (152.82M) | (208.97M) | (200.19M) | (227.03M) | [{"date":"2019-12-31","value":-7839100000,"profit":false},{"date":"2020-12-31","value":-15281700000,"profit":false},{"date":"2021-12-31","value":-20896600000,"profit":false},{"date":"2022-12-31","value":-20018600000,"profit":false},{"date":"2023-12-31","value":-22703500000,"profit":false}] |
Total Non-Operating Income/Expense | 19.57M | 13.18M | 3.34M | (364.00K) | 878.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.35,"profit":true},{"date":"2021-12-31","value":17.05,"profit":true},{"date":"2022-12-31","value":-1.86,"profit":false},{"date":"2023-12-31","value":4.49,"profit":true}] |
Pre-Tax Income | (68.61M) | (146.23M) | (207.30M) | (200.37M) | (225.30M) | [{"date":"2019-12-31","value":-6860600000,"profit":false},{"date":"2020-12-31","value":-14622700000,"profit":false},{"date":"2021-12-31","value":-20729800000,"profit":false},{"date":"2022-12-31","value":-20036800000,"profit":false},{"date":"2023-12-31","value":-22530400000,"profit":false}] |
Income Taxes | (9.79M) | (6.59M) | (1.69M) | (57.90M) | (54.00K) | [{"date":"2019-12-31","value":-978500000,"profit":false},{"date":"2020-12-31","value":-659000000,"profit":false},{"date":"2021-12-31","value":-168700000,"profit":false},{"date":"2022-12-31","value":-5790400000,"profit":false},{"date":"2023-12-31","value":-5400000,"profit":false}] |
Income After Taxes | (58.82M) | (139.64M) | (205.61M) | (142.46M) | (225.25M) | [{"date":"2019-12-31","value":-5882100000,"profit":false},{"date":"2020-12-31","value":-13963700000,"profit":false},{"date":"2021-12-31","value":-20561100000,"profit":false},{"date":"2022-12-31","value":-14246400000,"profit":false},{"date":"2023-12-31","value":-22525000000,"profit":false}] |
Income From Continuous Operations | (68.61M) | (146.23M) | (207.30M) | (200.37M) | (196.01M) | [{"date":"2019-12-31","value":-6860600000,"profit":false},{"date":"2020-12-31","value":-14622700000,"profit":false},{"date":"2021-12-31","value":-20729800000,"profit":false},{"date":"2022-12-31","value":-20036800000,"profit":false},{"date":"2023-12-31","value":-19600600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (58.82M) | (139.64M) | (205.61M) | (142.46M) | (225.25M) | [{"date":"2019-12-31","value":-5882100000,"profit":false},{"date":"2020-12-31","value":-13963700000,"profit":false},{"date":"2021-12-31","value":-20561100000,"profit":false},{"date":"2022-12-31","value":-14246400000,"profit":false},{"date":"2023-12-31","value":-22525000000,"profit":false}] |
EPS (Diluted) | (1.69) | (1.11) | (1.47) | (1.41) | (1.38) | [{"date":"2019-12-31","value":-169,"profit":false},{"date":"2020-12-31","value":-111,"profit":false},{"date":"2021-12-31","value":-147,"profit":false},{"date":"2022-12-31","value":-141,"profit":false},{"date":"2023-12-31","value":-138,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ADPT | |
---|---|
Cash Ratio | 2.78 |
Current Ratio | 3.52 |
Quick Ratio | 3.38 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ADPT | |
---|---|
ROA (LTM) | -16.37% |
ROE (LTM) | -66.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ADPT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.60 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.40 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ADPT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.43 |
P/B | 4.30 |
Price/FCF | NM |
EV/R | 4.57 |
EV/Ebitda | NM |
PEG | NM |
Adaptive Biotechnologies Corp (ADPT) share price today is $5.97
Yes, Indians can buy shares of Adaptive Biotechnologies Corp (ADPT) on Vested. To buy Adaptive Biotechnologies Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Adaptive Biotechnologies Corp (ADPT) via the Vested app. You can start investing in Adaptive Biotechnologies Corp (ADPT) with a minimum investment of $1.
You can invest in shares of Adaptive Biotechnologies Corp (ADPT) via Vested in three simple steps:
The 52-week high price of Adaptive Biotechnologies Corp (ADPT) is $7.07. The 52-week low price of Adaptive Biotechnologies Corp (ADPT) is $2.28.
The price-to-earnings (P/E) ratio of Adaptive Biotechnologies Corp (ADPT) is
The price-to-book (P/B) ratio of Adaptive Biotechnologies Corp (ADPT) is 4.30
The dividend yield of Adaptive Biotechnologies Corp (ADPT) is 0.00%
The market capitalization of Adaptive Biotechnologies Corp (ADPT) is $1.00B
The stock symbol (or ticker) of Adaptive Biotechnologies Corp is ADPT